Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes
Lawrence H. Young(Yale University), for the DIAD Investigators, Steven D. Wittlin(University of Rochester), Janice A. Davey(Yale University), Raymond Taillefer(Université de Montréal), Frans J. Th. Wackers(Yale University), Eugene J. Barrett(University of Virginia), Neil Filipchuk, Robert E. Ratner(W.K. Kellogg Foundation), Ami E. Iskandrian(University of Alabama at Birmingham), Deborah Chyun(University of Connecticut), Gary V. Heller(Institute for Community Living), Silvio E. Inzucchi(Yale University)
Cited by 817
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
|Diabetes Care|2012|3.2k